Ibakin 100

• Newly diagnosed Ph+ CML (chronic phase)
• Ph+ CML (blast crisis, accelerated phase, or after interferon-alpha therapy failure)
• Relapsed or refractory Ph+ ALL (adults)
• Newly diagnosed Ph+ ALL (pediatric, in combination with chemotherapy)
• MDS/MPD (with PDGFR gene re-arrangements)
• Aggressive systemic mastocytosis (without D816V c-Kit mutation)
• Hypereosinophilic syndrome/eosinophilic leukemia (with FIP1L1-PDGFRα fusion kinase)
• Unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans
• Kit (CD117) positive unresectable and/or metastatic malignant GIST
• Adjuvant treatment of GIST (after complete gross resection)

Adult Dose (Oral):

• Ph+ CML CP: 400 mg/day
• Ph+ CML AP or BC: 600 mg/day
• Ph+ ALL: 600 mg/day
• MDS/MPD: 400 mg/day
• ASM: 100 mg/day or 400 mg/day
• HES/CEL: 100 mg/day or 400 mg/day
• DFSP: 800 mg/day (400 mg twice daily)
• GIST (metastatic/unresectable): 400 mg/day
• GIST (adjuvant): 400 mg/day × 3 years

Child Dose (Oral):

• Ph+ CML CP: 340 mg/m2/day (max 600 mg/day)
• Ph+ ALL: 340 mg/m2/day (max 600 mg/day)

Hepatic Impairment: Severe: Reduce dose by 25%

Common Side Effects:

• Abdominal pain
• Diarrhea
• Fatigue
• Muscle cramp
• Musculoskeletal pain
• Nausea
• Rash
• Vomiting

Serious: Fluid retention and edema, hematologic toxicity, congestive heart failure, hepatotoxicity, hemorrhage, tumor lysis syndrome, hypothyroidism

Precautions:

• Imatinib may affect your ability to drive (dizziness, blurred vision)
• Fluid retention and edema: Monitor weight regularly
• Cytopenias: Weekly CBC for first month, biweekly for second month
• Hepatotoxicity: Monitor liver function before and monthly during treatment
• Monitor patients with cardiac disease or risk factors
• Apprise pregnant women of potential harm to fetus